MASON, Ohio --(BUSINESS WIRE)--Jan. 13, 2020-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced preliminary financial results for the fourth quarter and full year 2019 and provided 2020 financial
MASON, Ohio --(BUSINESS WIRE)--Jan. 7, 2020-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the successful completion of patient enrollment in the aMAZE™ clinical trial.
MASON, Ohio --(BUSINESS WIRE)--Dec. 16, 2019-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that the company will be participating in the upcoming 38th Annual JP Morgan Healthcare
MASON, Ohio --(BUSINESS WIRE)--Dec. 4, 2019-- AtriCure, Inc. (Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Karen Prange and Daniel Florin have been named to its Board of Directors. Ms.
MASON, Ohio --(BUSINESS WIRE)--Nov. 12, 2019-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that the company will be participating in the upcoming Piper Jaffray 31 st Annual
MASON, Ohio --(BUSINESS WIRE)--Nov. 12, 2019-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that the company will be participating in the upcoming Piper Jaffray 31 st Annual
Worldwide revenue of $56.6 million – an increase of 13.4% year over year U.S. revenue of $46.1 million – an increase of 16.0% year over year International revenue of $10.5 million – an increase of 3.1% year over year MASON, Ohio --(BUSINESS WIRE)--Oct. 30, 2019-- AtriCure, Inc.
Worldwide revenue of $56.6 million – an increase of 13.4% year over year U.S. revenue of $46.1 million – an increase of 16.0% year over year International revenue of $10.5 million – an increase of 3.1% year over year MASON, Ohio --(BUSINESS WIRE)--Oct. 30, 2019-- AtriCure, Inc.
MASON, Ohio --(BUSINESS WIRE)--Oct. 21, 2019-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in upcoming investor conferences.
MASON, Ohio --(BUSINESS WIRE)--Oct. 21, 2019-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in upcoming investor conferences.
MASON, Ohio --(BUSINESS WIRE)--Oct. 8, 2019-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2019 financial results on Wednesday, October 30, 2019
MASON, Ohio --(BUSINESS WIRE)--Oct. 8, 2019-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2019 financial results on Wednesday, October 30, 2019
Clinical evidence demonstrates that AtriClip ® devices exclude and electrically isolate the left atrial appendage MASON, Ohio --(BUSINESS WIRE)--Aug. 27, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage (LAA)
Clinical evidence demonstrates that AtriClip ® devices exclude and electrically isolate the left atrial appendage MASON, Ohio --(BUSINESS WIRE)--Aug. 27, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage (LAA)
MASON, Ohio --(BUSINESS WIRE)--Aug. 26, 2019-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that the company will be participating in the upcoming Morgan Stanley 17 th Annual Global
